Trial · NCT07037758
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Up to 2.5 years | Clinically significant changes in vital signs and clinical laboratory tests will be reported as adverse events. |
| Primary | Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs) | Up to 35 days | |
| Secondary | Maximum Serum Concentration (Cmax) of Tarlatamab | Up to approximately 21 weeks | |
| Secondary | Minimum Serum Concentration (Cmin) of Tarlatamab | Up to approximately 21 weeks | |
| Secondary | Area Under the Concentration-time Curve (AUC) of Tarlatamab | Up to approximately 21 weeks | |
| Secondary | Half-life (t1/2) of Tarlatamab | Up to approximately 21 weeks | |
| Secondary | Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | Up to 2.5 years | |
| Secondary | Duration of Response (DOR) per RECIST 1.1 | Up to 2.5 years | |
| Secondary | Time to Response (TTR) per RECIST 1.1 | Up to 2.5 years | |
| Secondary | Disease Control (DC) per RECIST 1.1 | Up to 2.5 years | |
| Secondary | Progression-free Survival (PFS) per RECIST 1.1 | Up to 2.5 years | |
| Secondary | Time to Progression (TTP) per RECIST 1.1 | Up to 2.5 years | |
| Secondary | Time to Subsequent Therapy | Up to 2.5 years | |
| Secondary | Overall Survival (OS) | Up to 2.5 years | |
| Secondary | Number of Participants with Anti-AB248 Antibody Formation | Up to 2.5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07037758/registered